Ian Cromwell

A prospective clinical utility and pharmacoeconomic study of the impact of the 21-gene Recurrence Score® assay in oestrogen receptor positive node negative breast cancer

James Davidson, Ian Cromwell, Susan Ellard et al. · European Journal of Cancer · 2013 · 54 citations

Breast Oncology, Medicine, 21-Gene Recurrence Score® +8

Resource Utilization and Costs during the Initial Years of Lung Cancer Screening with Computed Tomography in Canada

Sonya Cressman, Stephen Lam, Martin C. Tammemägi et al. · Journal of Thoracic Oncology · 2014 · 50 citations · Full text

Erlotinib or Docetaxel for Second-Line Treatment of Non-small Cell Lung Cancer: A Real-World Cost-Effectiveness Analysis

Ian Cromwell, Kimberly van der Hoek, Barbara Melosky et al. · Journal of Thoracic Oncology · 2011 · 27 citations · Full text

Second-line Treatment, Oncology, Real-world Cost-effectiveness Analysis +8

Erlotinib or best supportive care for third-line treatment of advanced non-small-cell lung cancer: A real-world cost-effectiveness analysis

Ian Cromwell, Kimberly van der Hoek, Suzanne C. Malfair Taylor et al. · Lung Cancer · 2012 · 25 citations

Medicine, Real-world Cost-effectiveness Analysis, Cancer Management +7

Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada

Ian Cromwell, Dean A. Regier, Stuart Peacock et al. · The Oncologist · 2016 · 21 citations · Full text